Treatment of invasive infections due to rare or emerging yeasts and moulds.

about

Pseudo-outbreak of Lecanicillium and Acremonium species in orthopedic surgery patients.Synthesis and in vitro and in vivo antifungal activity of the hydroxy metabolites of saperconazole.

P2860

Q36414024-7527B3B1-65B4-48EF-86A1-1740AFF90AA4 Q43105019-CEACE0EF-9135-4C4B-A6AC-C8AA48F19FA6

P2860

Treatment of invasive infections due to rare or emerging yeasts and moulds.

Item

http://www.wikidata.org/entity/Q36491806

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Treatment of invasive infections due to rare or emerging yeasts and moulds.

@ast

Treatment of invasive infections due to rare or emerging yeasts and moulds.

@en

type

Item

label

Treatment of invasive infections due to rare or emerging yeasts and moulds.

@ast

Treatment of invasive infections due to rare or emerging yeasts and moulds.

@en

prefLabel

Treatment of invasive infections due to rare or emerging yeasts and moulds.

@ast

Treatment of invasive infections due to rare or emerging yeasts and moulds.

@en

P1476

Treatment of invasive infections due to rare or emerging yeasts and moulds.

@en

P2093

Gulsen Ozkaya Sahin

http://www.w3.org/2001/XMLSchema#string

P2860

Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units

Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates

Penicillium marneffei: types and drug susceptibility.

Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy.

Human fusariosis.

Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study.

Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.

Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B.

P304

1181-1190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1517/14656566.7.9.1181

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Murat Akova

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16732704

http://www.w3.org/2001/XMLSchema#string

Treatment of invasive infections due to rare or emerging yeasts and moulds.

about

P2860

P2860

Treatment of invasive infections due to rare or emerging yeasts and moulds.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698